HERNDON, Va.--(BUSINESS WIRE)--Guardian Technologies International, Inc. (OTCBB:GDTI), a leading provider of high-performance security and healthcare solutions, announced today that the clinical survey results employing their Signature Mapping™ CAD technology have demonstrated that it is capable of accurately detecting and characterizing tumors in screening mammograms. Most importantly, the study found that Signature Mapping™ CAD is a highly sensitive tool for accurately detecting lesions in dense breast tissue that are undetectable with the human eye. In one clinical case using a multi-year longitudinal study, Guardian’s technology indicated the presence of a developing lesion four years before it was diagnosed and confirmed by biopsy as being a cancerous tumor.
